{"schema_version":"1","generated_at":"2026-11-13T20:38:54.850Z","data_as_of":null,"url":"https://www.findmykol.com/kol/ibrahim-muhsen","json_url":"https://www.findmykol.com/kol/ibrahim-muhsen/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"ibrahim-muhsen","name":"Ibrahim Muhsen","credential":"MD","specialty":"Hematology / Oncology","specialty_raw":"Hematology & Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Birmingham","state":"AL","region":{"label":"Southeast","url":"https://www.findmykol.com/region/southeast"}},"identifiers":{"npi":"1073175105","orcid":"0000-0002-7156-2532","openalex":"A5059992438"},"summary":"Ibrahim Muhsen is an Oncology physician. OpenAlex indexes 102 publications with 739 citations (h-index 14).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":102,"cited_by_count":739,"h_index":14,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":1,"program_years":{"first":2021,"last":null},"rows_total":1,"shown":1,"withheld":0,"rows":[{"payer":"Genentech USA, Inc.","program_year":2024,"amount_usd":20.66,"payment_count":1,"source_url":"https://openpaymentsdata.cms.gov/search?query=1073175105"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1073175105","source":"payments"},"prescribing":{"data_year":2021,"areas_total":1,"areas_shown":1,"areas":[{"area":"Cardiovascular","share_pct":100,"classes_total":1,"classes":[{"class":"Statin","setting":"prescribed","share_pct":100,"drugs":[{"name":"Atorvastatin Calcium","share_pct":100}],"max_beneficiaries":null}]}],"source":"medicare"},"publications":{"total":50,"shown":5,"withheld":45,"matched_by":"OpenAlex author record","recent":[{"title":"Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2024015779","status":"verified"},{"title":"CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia","year":2025,"journal":"Blood Advances","source_url":"https://doi.org/10.1182/bloodadvances.2025017526","status":"verified"},{"title":"Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real world","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-516","status":"verified"},{"title":"Patient characteristics, toxicity, and response after real world administration of obecabtagene autoleucel and brexucabtagene autoleucel for relapsed acute lymphoblastic leukemia: A rocca analysis","year":2025,"journal":"Blood","source_url":"https://doi.org/10.1182/blood-2025-2715","status":"verified"},{"title":"Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.24.00321","status":"verified"}],"source":"works"},"contact":{"address_1":"2000 6TH AVE S","city":"Birmingham","state":"AL","zip":"352332110","phone":"205-934-9999","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1073175105","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Stuart Orkin","slug":"stuart-orkin","institution":"Harvard Medical School","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/stuart-orkin","json_url":"https://www.findmykol.com/kol/stuart-orkin/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"publications":45}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-08-13","provider_certified":"2025-08-13","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2021}},"methodology_url":"https://www.findmykol.com/about#methodology"}